The Evaluation Of Novel Βeta-Lactam Antibiotics On Clinical Bacterial Isolates. Melvin Grimes 1, Adrienne Murphy 1,Jason Carr 2,and Debra Jackson 1, 1 Department of Biology, University of Louisiana at Monroe, Monroe,LA and School of Science and Technology 2, Nazarbayev University, Astana Kazakhstan Materials and Methods Strains: Clinical isolate of Escherichia coli and Staphylococcus aureus were used. Media: Mueller Hinton Agar (MH) is used to test antibiotic efficacy. Novel Antibiotics Used: PDK94,Bis-2-pyridyl,HTS10, 3PD07, 3PDK08, Benzene Tellurinic (sodium salt), 2PDK42A,PDK 19, LEB 77,and LEB 78 Assay: Each antibiotic was suspended in 10 mls of 100% ethanol. The clinical isolates were grown overnight then diluted for the antibiotic disc assay. Each isolate was spread on a MH agar plate in triplets. Sterile paper disc were dipped in the antibiotic, placed on the plate, and incubated at 37 o C overnight. Each zone of inhibition was measured. Conclusions The E.coli isolates were sensitive toward the novel antibotics Benzene tellurinic and Bis-2-pyridyl. The novel antibiotics PDK94 and HTS10 also proved to be effective against the E.coli isolates The novel antibiotics 3PDK08,3PDK07,2PDK42A,and PDK 19,LEB77,LEB78,Benzene Tellurinic (sodium salt), and Bis- 2-pyridyl were most effective against Staph.aureus. Measured Zones of Inhibition The data table shows the average zone of inhibition of the antibiotic over three test trials and the standard deviation for each antibiotic tested. ResultsFuture Direction Additional clinical E. coli isolates and clinical Staphylococcoal isolates will be tested for antibiotic susceptibility to the novel beta-lactams presented here. References Antimicrobial Agents in the Treatment of Infectious Disease." Online Textbook of Bacteriology. Web. 29 Nov "Escherichia Coli." MicrobeWiki. Web. 29 Nov The Microbial World :: A Look at All Things Small. Web. 29 Nov AbstractIntroduction Results Zones of inhibition for Bis-2-pyridyl and Benzene Tellurinic showing sensitivity toward the E. coli Zones of inhibition for HTS10 and PDK 94 showing sensitivity toward the E. coli. The distribution and occurrence of multi-drug resistant bacteria is an increasing public health problem. The emergence of resistant bacteria makes the task of synthesizing new antibiotics imperative to combating these bacteria. In this study, the new beta-lactam antibiotics are tested for broad spectrum activity using clinical E. coli and Staphylococcus aureus strains. The clinical isolates were grown over night and spread on Mueller Hinton (MH) agar. The novel beta-lactam antibiotics were placed on sterile disc and placed on the MH plates, incubated overnight, and each zone of inhibition was measured. Our results show several novel antibiotics are effective against the clinical isolates. Antibiotics Zone of Inhibition Average (mm) HTS1013±2 Bis-2-pyridyl21±1 PDK 9415±0 Bentel22±2 Antibiotics Zone of Inhibition Average (mm) 3PDK0714±1.55 3PDK0815±1.11 2PDK42A12±1.11 PDK1912±.44 LEB 7710±.45 LEB 7813±.67 Benzene Telluric Acid (sodium salt) 16±1.34 Bis-2-pyridyl15±1.34 Beta-lactam antibiotics consist of a broad class of antibiotics including penicillins, cephalosporins, carbapenems, and monobactams. The mechanism of these antibiotics involves the inhibition of cell wall synthesis by inactivating transpeptidase an enzyme responsible for the cross linkage of peptides of peptidoglycan. Both Staphylococcus aureus and Escherichia coli are a part of the body’s normal flora found on the skin and intestines respectively. In the case of S. aureus an opportunistic pathogen, infections range from minor skin infections such as pimples and boils to grave illnesses such as endocarditis and toxic shock syndrome (TSS). Many strains of E. coli can also cause disease and illness in both the immunocompromised and the healthy. E.coli can also produce toxins are responsible for several food borne diseases such as E. coli 0157:H7. Additional antimicrobial therapies against these organisms are needed. This study was undertaken to test the efficacy of novel beta- lactams antibiotics against clinical Staph and E.coli strains. Zones of inhibition for 3PDK07 and PDK19 showing sensitivity toward the Staph. aureus Zones of inhibition for Benzene Tellurinic and Bis-2-pyridyl showing sensitivity toward the Staph. aureus Zones of Inhibition for 3PDK08 and LEB78 showing sensitivity toward the Staph. aureus Donlan RM, Costerton JW Biofilms: surviral mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. Apr;15(2):